Cover Image
市場調查報告書

瀰漫性大B細胞淋巴瘤:全球臨床實驗趨勢

Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H2, 2017

出版商 GlobalData 商品編碼 297511
出版日期 內容資訊 英文 849 Pages
訂單完成後即時交付
價格
Back to Top
瀰漫性大B細胞淋巴瘤:全球臨床實驗趨勢 Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H2, 2017
出版日期: 2017年07月26日 內容資訊: 英文 849 Pages
簡介

本報告提供瀰漫性大B細胞淋巴瘤相關之臨床研究最新趨勢分析,以疾病概要為首,提供您主要的已開發國家·新興國家之臨床實驗狀況,各地區及各階段的進展,彙整受驗者的募集情況,有潛力的贊助商,各企業及研究機關的研究進行狀況,有潛力的藥劑比較等資訊。

本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 亞太地區主要5國的臨床實驗數量
    • 歐洲主要5國的臨床實驗數量
    • 北美主要國家的臨床實驗數量
    • 中東·非洲主要5國的臨床實驗數量
    • 中南美主要5國的臨床實驗數量

G7各國臨床實驗數量:癌症治療藥臨床實驗上瀰漫性大B細胞淋巴瘤的比例

G7各國的各階段臨床實驗數量

G7各國臨床實驗數量:各進展狀況

E7各國臨床實驗數量:癌症治療藥臨床實驗上瀰漫性大B細胞淋巴瘤的比例

E7各國的各階段臨床實驗數量

E7各國臨床實驗數量:各進展狀況

各階段臨床實驗數量

  • 進行中的臨床實驗:各階段

各進展狀況臨床實驗數量

臨床實驗的目標達成情形

一定期間所採用的實驗對像

贊助商類別的臨床實驗數量

有潛力的贊助商

瀰漫性大B細胞淋巴瘤治療藥臨床實驗主要的參與企業

有潛力的藥劑

最新臨床實驗新聞

臨床實驗簡介概要

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC4393CTIDB

GlobalData's clinical trial report, "Diffuse Large B-Cell Lymphoma Global Clinical Trials Review, H2, 2017" provides an overview of Diffuse Large B-Cell Lymphoma clinical trials scenario. This report provides top line data relating to the clinical trials on Diffuse Large B-Cell Lymphoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 4
  • List of Figures 5
  • Report Guidance 6
  • GlobalData Clinical Trials Report Coverage 7
  • Clinical Trials by Region 8
  • Clinical Trials and Average Enrollment by Country 9
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 12
  • Top Five Countries Contributing to Clinical Trials in Europe 13
  • Top Countries Contributing to Clinical Trials in North America 14
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 15
  • Top Five Countries Contributing to Clinical Trials in Central and South America 16
  • Clinical Trials by G7 Countries: Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials 17
  • Clinical Trials by Phase in G7 Countries 19
  • Clinical Trials in G7 Countries by Trial Status 20
  • Clinical Trials by E7 Countries: Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials 22
  • Clinical Trials by Phase in E7 Countries 24
  • Clinical Trials in E7 Countries by Trial Status 25
  • Clinical Trials by Phase 27
  • In Progress Trials by Phase 28
  • Clinical Trials by Trial Status 29
  • Clinical Trials by End Point Status 31
  • Subjects Recruited Over a Period of Time 32
  • Clinical Trials by Sponsor Type 33
  • Prominent Sponsors 34
  • Top Companies Participating in Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials 36
  • Prominent Drugs 38
  • Latest Clinical Trials News on Diffuse Large B-Cell Lymphoma 39
  • Jul 11, 2017: ArQule Announces First Patient Dosed in Phase 1 Trial of BTK Inhibitor, ARQ 531, for B-cell Malignancies 39
  • Jun 23, 2017: ArQule Presents Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association 39
  • Jun 23, 2017: Karyopharm Reports Updated Phase 2b SADAL Data for Selinexor in Diffuse Large B-Cell Lymphoma at the 2017 European Hematology Association Annual Meeting 40
  • Jun 15, 2017: TG Therapeutics Announces Follow-Up Data from the Triple Combination of TG-1101, TGR-1202, and Bendamustine in Patients with DLBCL and FL at the 14th International Conference on Malignant Lymphoma 41
  • Jun 14, 2017: Epizyme Reports Positive Interim Data from Phase 2 Trial for Tazemetostat in Relapsed or Refractory Follicular Lymphoma and DLBCL Patients 41
  • Jun 14, 2017: Oxford BioMedica Notes Findings on CTL019 from Phase II JULIET Study Presented at the 14th Meeting of International Conference on Malignant Lymphoma 42
  • Jun 07, 2017: Novartis interim results from global, pivotal CTL019 trial show durable complete responses in adults with r/r DLBCL 43
  • Jun 05, 2017: HalioDx highlights use of Immunosign to define CAR T-cell therapy signature in tumor at ASCO 2017 43
  • Jun 05, 2017: MorphoSys Presents First Safety and Efficacy Data of MOR208 in Combination with Lenalidomide from a Phase 2 Study in DLBCL 44
  • Jun 02, 2017: Spectrum Pharmaceuticals Announces Presentation on MARQIBO at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, June 2-6, 2017 45
  • May 18, 2017: Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association 45
  • May 18, 2017: ArQule to Present Preclinical Data for BTK Inhibitor, ARQ 531, at the 22nd Annual Congress of the European Hematology Association 45
  • May 18, 2017: MorphoSys to Present Clinical Data on MOR-208 at Upcoming ASCO Annual Meeting 2017 46
  • May 18, 2017: Karyopharm's Phase 2b SADAL Data Evaluating Selinexor in Diffuse Large B-Cell Lymphoma Selected for Oral Presentation at the 2017 European Hematology Association Annual Meeting 46
  • May 17, 2017: Juno Therapeutics to Present Key Clinical Data Updates on JCAR017 at the 2017 American Society of Clinical Oncology Annual Meeting 47
  • May 16, 2017: Immunovaccines Lead Immuno-Oncology Candidate to Enter Investigator-Sponsored Phase 2 Clinical Trial in DLBCL in Combination with Approved Anti-PD-1 Drug 47
  • Apr 25, 2017: Epizyme Announces Tazemetostat Fast Track Designation for Follicular Lymphoma and Plenary Session on Phase 2 NHL Data at ICML 48
  • Clinical Trial Profile Snapshots 49

Appendix 847

  • Abbreviations 847
  • Definitions 847
  • Research Methodology 848
  • Secondary Research 848
  • About GlobalData 849
  • Contact Us 849
  • Disclaimer 849
  • Source 849

List of Tables

List of Tables

  • Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Region, 2017* 8
  • Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 10
  • Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 12
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 13
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, North America, Top Countries, 2017* 14
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2017* 15
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 16
  • Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2017* 18
  • Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
  • Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 21
  • Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2017* 23
  • Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 24
  • Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 26
  • Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Phase, 2017* 27
  • Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 28
  • Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2017* 30
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2017* 31
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 32
  • Diffuse Large B-Cell Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 33
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 35
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 37
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 38

List of Figures

List of Figures

  • Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Region (%), 2017* 8
  • Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 9
  • Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 11
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 12
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 13
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 14
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2017* 15
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 16
  • Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, G7 Countries (%), 2017* 17
  • Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 19
  • Diffuse Large B-Cell Lymphoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20
  • Proportion of Diffuse Large B-Cell Lymphoma to Oncology Clinical Trials, E7 Countries (%), 2017* 22
  • Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 24
  • Diffuse Large B-Cell Lymphoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 25
  • Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Phase (%), 2017* 27
  • Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 28
  • Diffuse Large B-Cell Lymphoma Therapeutics, Global, Clinical Trials by Trial Status, 2017* 29
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, by End Point Status, 2017* 31
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 32
  • Diffuse Large B-Cell Lymphoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 33
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 34
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 36
  • Diffuse Large B-Cell Lymphoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 38
  • GlobalData Methodology 848
Back to Top